Literature DB >> 22819302

Preventive and protective effects of silymarin on doxorubicin-induced testicular damages correlate with changes in c-myc gene expression.

H Malekinejad1, H Janbaz-Acyabar, M Razi, S Varasteh.   

Abstract

This study aimed to investigate the preventive and protective effects of silymarin (SMN) on doxorubicin (DOX)-induced damages in the testis. Wistar rats were divided into six groups (n=8), including: control (C), DOX-treated (DOX, 15 mg/kg, i.p.), DOX- and SMN-treated and SMN-treated animals (SMN, 50 mg/kg, orally). Those groups, which received either compounds, were sub-grouped based on the preventive (PVT), protective (PTT) and/or therapeutic regimens (TPT) of SMN administration. The antioxidant status analyses, hormonal assay, and histopathological examinations in the testis were conducted. The expression of c-myc at mRNA level also was analyzed. SMN in preventive and protective forms significantly (p<0.05) improved the DOX-induced weight loss and lowered the alkaline phosphatase level. Pretreatment and co-treatment with SMN attenuated the DOX-induced carbonyl stress. The DOX-induced histopathological damages including negative TDI and IR were significantly (p<0.05) improved with SMN pretreatment and co-administration. SMN in preventive and protective forms prevented from DOX-induced DNA fragmentation in the testis. SMN ameliorated the DOX-reduced serum level of sexual hormones including testosterone, inhibin B, LH and FSH in PVT and PTT groups. The c-myc expression at mRNA level was completely and relatively down regulated in the testis of animals that received SMN as pretreatment and concurrent administration, respectively. Our data suggests that the DOX-induced biochemical and histopathological alterations could be prevented and/or protected by SMN. Moreover, the SMN protective and preventive effects attribute to its capacity in the reduction of DOX-induced carbonyl stress and DNA damage, which may be mediated by c-myc expression.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22819302     DOI: 10.1016/j.phymed.2012.06.011

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  6 in total

1.  Perturbation of epigenetic processes by doxorubicin in the mouse testis.

Authors:  Oluwajoba O Akinjo; Timothy W Gant; Emma L Marczylo
Journal:  Toxicol Res (Camb)       Date:  2016-06-01       Impact factor: 3.524

2.  Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats.

Authors:  Hassan Malekinejad; Shirin Rokhsartalab-Azar; Sepideh Hassani-Dizaj; Shahin Alizadeh-Fanalou; Aysa Rezabakhsh; Amir Amniattalab
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-18       Impact factor: 2.441

3.  In vitro cytotoxicity analysis of doxorubicin-loaded/superparamagnetic iron oxide colloidal nanoassemblies on MCF7 and NIH3T3 cell lines.

Authors:  Katerina Tomankova; Katerina Polakova; Klara Pizova; Svatopluk Binder; Marketa Havrdova; Mary Kolarova; Eva Kriegova; Jana Zapletalova; Lukas Malina; Jana Horakova; Jakub Malohlava; Argiris Kolokithas-Ntoukas; Aristides Bakandritsos; Hana Kolarova; Radek Zboril
Journal:  Int J Nanomedicine       Date:  2015-01-29

Review 4.  Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives.

Authors:  Peter F Surai
Journal:  Antioxidants (Basel)       Date:  2015-03-20

5.  Silymarin: A Novel Natural Agent to Restore Defective Pancreatic β Cells in Streptozotocin (STZ)-induced Diabetic Rats.

Authors:  Amir Amniattalab; Hassan Malekinejad; Aysa Rezabakhsh; Shirin Rokhsartalab-Azar; Shahin Alizade-Fanalou
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

6.  Simultaneous Administration of Dexamethasone and Vitamin E Reversed Experimental Varicocele-induced Impact in testicular tissue in Rats; Correlation with Hsp70-2 Chaperone Expression.

Authors:  Hajar Khosravanian; Mazdak Razi; Farah Farokhi; Narges Khosravanian
Journal:  Int Braz J Urol       Date:  2015 Jul-Aug       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.